iNtRON Biotechnology, Inc. (KOSDAQ:048530)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,020.00
+205.00 (5.37%)
Jan 29, 2026, 3:30 PM KST
-27.70%
Market Cap123.23B
Revenue (ttm)5.56B -35.5%
Net Income-6.29B
EPS-197.47
Shares Out30.65M
PE Ration/a
Forward PEn/a
Dividend100.00 (2.62%)
Ex-Dividend DateDec 29, 2025
Volume478,720
Average Volume260,551
Open3,780.00
Previous Close3,815.00
Day's Range3,690.00 - 4,050.00
52-Week Range2,895.00 - 5,700.00
Beta0.02
RSI74.73
Earnings DateJan 22, 2026

About iNtRON Biotechnology

iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 73
Stock Exchange KOSDAQ
Ticker Symbol 048530
Full Company Profile

Financial Performance

In 2024, iNtRON Biotechnology's revenue was 6.42 billion, a decrease of -33.05% compared to the previous year's 9.59 billion. Losses were -2.59 billion, -73.27% less than in 2023.

Financial Statements